

Jennifer R Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8158051/publications.pdf>

Version: 2024-02-01

303
papers

20,706
citations

17405

63
h-index

11030

137
g-index

307
all docs

307
docs citations

307
times ranked

19627
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 311-322.	13.9	1,532
2	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	13.9	1,427
3	Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. <i>Cell</i> , 2013, 152, 714-726.	13.5	1,202
4	<i>MYD88</i> and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2011, 365, 2497-2506.	13.9	1,021
5	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	13.9	785
6	Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. <i>Journal of Clinical Oncology</i> , 2012, 30, 488-496.	0.8	719
7	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. <i>New England Journal of Medicine</i> , 2018, 379, 2517-2528.	13.9	706
8	Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. <i>Nature</i> , 2014, 511, 616-620.	13.7	698
9	Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 β , for relapsed/refractory chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 3390-3397.	0.6	562
10	Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. <i>Journal of Clinical Investigation</i> , 2007, 117, 112-121.	3.9	521
11	<i>MYD88</i> L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. <i>Blood</i> , 2013, 121, 2051-2058.	0.6	368
12	Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2014, 26, 813-825.	7.7	323
13	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	2.0	305
14	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 1409-1418.	5.1	290
15	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016, 7, 11589.	5.8	285
16	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 112, 1923-1930.	0.6	282
17	Management of adverse events associated with idelalisib treatment: expert panel opinion. <i>Leukemia and Lymphoma</i> , 2015, 56, 2779-2786.	0.6	268
18	Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. <i>Lancet</i> , The, 2021, 397, 892-901.	6.3	260

#	ARTICLE	IF	CITATIONS
19	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	0.6	259
20	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	0.6	248
21	A phase 1 study of the PI3K \hat{I} inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). <i>Blood</i> , 2014, 123, 3398-3405.	0.6	245
22	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. <i>Blood</i> , 2016, 127, 3215-3224.	0.6	242
23	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. <i>Cancer Cell</i> , 2019, 36, 369-384.e13.	7.7	224
24	PI3K inhibitors are finally coming of age. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 741-769.	21.5	222
25	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2017, 18, 297-311.	5.1	219
26	Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase \hat{I} , as therapy for previously treated indolent non-Hodgkin lymphoma. <i>Blood</i> , 2014, 123, 3406-3413.	0.6	203
27	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , 2017, 102, 1796-1805.	1.7	200
28	Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematology</i> , the, 2017, 4, e114-e126.	2.2	181
29	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	0.6	178
30	Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2016, 30, 750-763.	7.7	173
31	Cardiovascular Toxicities Associated With Ibrutinib. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1667-1678.	1.2	169
32	Ventricular arrhythmias and sudden death in patients taking ibrutinib. <i>Blood</i> , 2017, 129, 2581-2584.	0.6	161
33	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-31.	0.8	152
34	Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. <i>Blood Advances</i> , 2019, 3, 1553-1562.	2.5	145
35	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	0.6	130
36	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , 2016, 172, 735-744.	1.2	122

#	ARTICLE	IF	CITATIONS
37	Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 2208-2214.	0.8	117
38	Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. <i>Blood</i> , 2012, 120, 3501-3509.	0.6	117
39	Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2011, 17, 2977-2986.	3.2	112
40	Predictors of Improved Progression-Free Survival After Nonmyeloablative Allogeneic Stem Cell Transplantation for Advanced Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 1056-1064.	2.0	110
41	The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF- κ B Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1576-1589.	3.2	108
42	Phosphatidylinositol 3-kinase $\hat{\Gamma}$ blockade increases genomic instability in B cells. <i>Nature</i> , 2017, 542, 489-493.	13.7	105
43	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 2915-2922.	0.6	104
44	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 2931-2940.	0.6	102
45	Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2018, 34, 982-995.e7.	7.7	101
46	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1b study. <i>Lancet Haematology</i> , 2019, 6, e38-e47.	2.2	98
47	How I treat CLL patients with ibrutinib. <i>Blood</i> , 2018, 131, 379-386.	0.6	92
48	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
49	Growth dynamics in naturally progressing chronic lymphocytic leukaemia. <i>Nature</i> , 2019, 570, 474-479.	13.7	86
50	Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. <i>Blood</i> , 2016, 128, 1609-1613.	0.6	85
51	Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials. <i>Current Hematologic Malignancy Reports</i> , 2013, 8, 1-6.	1.2	84
52	Association of Advanced Leukemic Stage and Skin Cancer Tumor Stage With Poor Skin Cancer Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Dermatology</i> , 2014, 150, 280.	2.0	83
53	Integrative Genomic Analysis Implicates Gain of <i>PIK3CA</i> at 3q26 and <i>MYC</i> at 8q24 in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2012, 18, 3791-3802.	3.2	76
54	Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2022, 23, 1031-1043.	5.1	76

#	ARTICLE	IF	CITATIONS
55	Clinical Mimics of Lymphoma. <i>Oncologist</i> , 2004, 9, 406-416.	1.9	75
56	A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. <i>British Journal of Haematology</i> , 2009, 145, 741-748.	1.2	75
57	Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. <i>Clinical Cancer Research</i> , 2017, 23, 735-745.	3.2	74
58	Targeting the B cell receptor pathway in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 2362-2370.	0.6	71
59	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. <i>British Journal of Haematology</i> , 2019, 184, 558-569.	1.2	71
60	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. <i>Blood</i> , 2016, 128, 2899-2908.	0.6	70
61	Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. <i>Blood</i> , 2016, 128, 574-583.	0.6	69
62	Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. <i>Blood</i> , 2015, 125, 2779-2785.	0.6	68
63	Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 163, 123-126.	1.2	67
64	Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, e295-e298.	1.7	67
65	Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. <i>Genome Research</i> , 2017, 27, 1300-1311.	2.4	67
66	Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. <i>Blood</i> , 2020, 136, 2918-2926.	0.6	67
67	Somatic mutation as a mechanism of Wnt/ β -catenin pathway activation in CLL. <i>Blood</i> , 2014, 124, 1089-1098.	0.6	65
68	PI3K δ -selective and PI3K δ / γ -combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1267-1279.	1.9	65
69	Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium. <i>Journal of Clinical Oncology</i> , 2014, 32, 2067-2073.	0.8	62
70	Long-Term Survival after Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1057-1065.	2.0	61
71	Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 42-48.	0.6	60
72	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.	2.2	60

#	ARTICLE	IF	CITATIONS
73	Are <i>BTK</i> and <i>PLCG2</i> mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?. <i>Expert Review of Hematology</i> , 2018, 11, 185-194.	1.0	58
74	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. <i>Mycoses</i> , 2019, 62, 1140-1147.	1.8	57
75	Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. <i>Blood Advances</i> , 2020, 4, 3977-3989.	2.5	55
76	Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 β , In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2010, 116, 1777-1777.	0.6	54
77	CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110 β , Demonstrates Clinical Activity and Pharmacodynamic Effects In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 55-55.	0.6	54
78	Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. <i>Nature</i> , 2021, 590, 157-162.	13.7	53
79	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1391-1402.	5.1	53
80	Phase I Trial of the Pan-PI3K Inhibitor Piliaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 3160-3169.	3.2	51
81	A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 89-95.	1.2	51
82	Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL). <i>Blood</i> , 2019, 134, 762-762.	0.6	50
83	Voxtalib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology</i> , the, 2018, 5, e170-e180.	2.2	44
84	Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 587-587.	0.6	43
85	PI3K p110 β inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression. <i>Journal of Clinical Investigation</i> , 2018, 129, 122-136.	3.9	42
86	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	2.5	40
87	Targeting Bruton's Tyrosine Kinase in CLL. <i>Frontiers in Immunology</i> , 2021, 12, 687458.	2.2	40
88	Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. <i>Leukemia</i> , 2021, 35, 3059-3072.	3.3	40
89	The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 110-118.	0.9	38
90	The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia. <i>Seminars in Oncology</i> , 2016, 43, 260-264.	0.8	38

#	ARTICLE	IF	CITATIONS
91	<i>miR-29</i> modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors. <i>Blood</i> , 2021, 137, 2481-2494.	0.6	37
92	Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia. <i>Blood</i> , 2021, 138, 44-56.	0.6	35
93	Lenalidomide in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 633-650.	1.9	34
94	Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. <i>Drugs and Aging</i> , 2017, 34, 509-527.	1.3	34
95	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	2.3	33
96	Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. <i>PLoS ONE</i> , 2015, 10, e0143685.	1.1	32
97	Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1b study. <i>Lancet Haematology</i> , 2021, 8, e912-e921.	2.2	32
98	Longitudinal Single-Cell Dynamics of Chromatin Accessibility and Mitochondrial Mutations in Chronic Lymphocytic Leukemia Mirror Disease History. <i>Cancer Discovery</i> , 2021, 11, 3048-3063.	7.7	31
99	Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 920-928.	0.6	30
100	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 1630-1630.	0.6	29
101	Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome. <i>Blood</i> , 2022, 139, 686-689.	0.6	29
102	Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2008, 143, 361-368.	1.2	28
103	Enhanced Activation and Expansion of T Cells Using Mechanically Soft Elastomer Fibers. <i>Advanced Biology</i> , 2018, 2, 1700167.	3.0	28
104	<i>Pneumocystis jirovecii</i> pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. <i>Blood Advances</i> , 2020, 4, 1458-1463.	2.5	28
105	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 32-32.	0.6	28
106	A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in <i>TP53</i> . <i>British Journal of Haematology</i> , 2014, 167, 149-161.	1.2	27
107	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	2.0	27
108	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. <i>Blood</i> , 2021, 138, 639-639.	0.6	27

#	ARTICLE	IF	CITATIONS
109	Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. <i>Leukemia and Lymphoma</i> , 2014, 55, 263-269.	0.6	26
110	A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. <i>Leukemia</i> , 2021, 35, 1064-1072.	3.3	25
111	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , 2021, 35, 3201-3211.	3.3	25
112	Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE™ Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2014, 124, 3331-3331.	0.6	24
113	Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. <i>Leukemia and Lymphoma</i> , 2013, 54, 1823-1825.	0.6	23
114	Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2019, 3, 1167-1174.	2.5	23
115	A Retrospective Analysis of <i>Pneumocystis jirovecii</i> Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. <i>Blood</i> , 2016, 128, 3705-3705.	0.6	23
116	Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e387-e398.	1.8	22
117	Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. <i>Blood</i> , 2016, 127, 2598-2606.	0.6	22
118	Phosphatidylinositol 3 Kinase $\hat{\Gamma}$ Inhibitors. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 394-400.	1.0	22
119	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 4113-4123.	2.5	22
120	Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities. <i>Blood</i> , 2015, 126, 497-497.	0.6	21
121	Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies. <i>Blood Advances</i> , 2021, 5, 3062-3065.	2.5	20
122	Controversial fluorescence <i>in situ</i> hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. <i>British Journal of Haematology</i> , 2015, 170, 694-703.	1.2	19
123	Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia. <i>Therapeutic Advances in Hematology</i> , 2018, 9, 3-19.	1.1	19
124	Simultaneous inhibition of Vps34 kinase would enhance PI3K $\hat{\Gamma}$ inhibitor cytotoxicity in the B-cell malignancies. <i>Oncotarget</i> , 2016, 7, 53515-53525.	0.8	19
125	Phase 1b dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. <i>Haematologica</i> , 2022, 107, 984-987.	1.7	19
126	Inherited predisposition to chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2008, 1, 51-61.	1.0	18

#	ARTICLE	IF	CITATIONS
127	Outcomes of Human Leukocyte Antigen–Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1390-1398.	2.0	18
128	<sc>MYD</sc>88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in <sc>CLL</sc>. <i>British Journal of Haematology</i> , 2019, 184, 925-936.	1.2	18
129	How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS–CoV–2 Pandemic. <i>HemaSphere</i> , 2020, 4, e432.	1.2	18
130	Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e317-e325.	1.8	17
131	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	17
132	Targeting constitutively active <sc>STAT3</sc> in chronic lymphocytic leukemia: A clinical trial of the <sc>STAT3</sc> inhibitor pyrimethamine with pharmacodynamic analyses. <i>American Journal of Hematology</i> , 2021, 96, E95-E98.	2.0	17
133	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 54-69.	2.6	16
134	Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. <i>Haematologica</i> , 2022, 107, 1335-1346.	1.7	16
135	LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2020, 136, 35-37.	0.6	16
136	Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 20-21.	0.6	16
137	Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy. <i>Blood</i> , 2016, 128, 621-621.	0.6	16
138	Richter's syndrome (RS) in patients with chronic lymphocytic leukemia (CLL) on novel agent therapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7505-7505.	0.8	16
139	Autologous Bone Marrow Transplantation for Marginal Zone Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2004, 45, 315-320.	0.6	15
140	Discovery of a Series of 5,11-Dihydro-6<i>H</i>-benzo[<i>e</i>]pyrimido[5,4-<i>b</i>][1,4]diazepin-6-ones as Selective PI3K- γ Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 908-912.	1.3	15
141	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021, 106, 3219-3222.	1.7	15
142	Ibrutinib Therapy Increases BCL-2 Dependence and Enhances Sensitivity to Venetoclax in CLL. <i>Blood</i> , 2015, 126, 490-490.	0.6	15
143	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016, 128, 3243-3243.	0.6	15
144	FISHing in the dark: How the combination of FISH and conventional karyotyping improves the diagnostic yield in CpG-stimulated chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016, 91, 978-983.	2.0	14

#	ARTICLE	IF	CITATIONS
145	Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. <i>Current Oncology Reports</i> , 2017, 19, 61.	1.8	14
146	IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K γ inhibitor idelalisib. <i>Haematologica</i> , 2021, 106, 2995-2999.	1.7	14
147	A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021, , .	3.3	14
148	Chronic Lymphocytic Leukemia: A Niche for Flavopiridol?. <i>Clinical Cancer Research</i> , 2005, 11, 3971-3973.	3.2	13
149	Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. <i>British Journal of Haematology</i> , 2010, 151, 336-345.	1.2	13
150	Inherited susceptibility to chronic lymphocytic leukemia: evidence and prospects for the future. <i>Therapeutic Advances in Hematology</i> , 2013, 4, 298-308.	1.1	13
151	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. <i>Blood</i> , 2020, 136, 46-47.	0.6	13
152	Small-Cell Cancers, and an Unusual Reaction to Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2437-2438.	0.8	12
153	Post-Transformation IGHV-IGHD-IGHJ Mutations in Chronic Lymphocytic Leukemia B Cells: Implications for Mutational Mechanisms and Impact on Clinical Course. <i>Frontiers in Oncology</i> , 2021, 11, 640731.	1.3	12
154	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. <i>Leukemia</i> , 2021, 35, 2854-2861.	3.3	12
155	Hodgkin disease associated with T-cell non-Hodgkin lymphomas: case reports and review of the literature. <i>American Journal of Clinical Pathology</i> , 2004, 121, 701-8.	0.4	12
156	A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Haematologica</i> , 2013, 98, 964-970.	1.7	11
157	Relapsed CLL: sequencing, combinations, and novel agents. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 248-255.	0.9	11
158	Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target. <i>Frontiers in Immunology</i> , 2021, 12, 662866.	2.2	11
159	Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): Up to four years follow-up of the RESONATE study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7510-7510.	0.8	11
160	Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 2989-2992.	0.8	10
161	The Role of Rituximab in Chronic Lymphocytic Leukemia Treatment and the Potential Utility of Biosimilars. <i>Oncologist</i> , 2018, 23, 288-296.	1.9	10
162	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10

#	ARTICLE	IF	CITATIONS
163	Idelalisib immune-related toxicity is associated with improved treatment response. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-6.	0.6	10
164	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016, 128, 641-641.	0.6	10
165	Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7520-7520.	0.8	10
166	Activation of <i>Notch</i> and <i>Myc</i> Signaling via B-cell "Restricted Depletion of <i>Dnmt3a</i> Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2021, 81, 6117-6130.	0.4	10
167	The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2287-2297.	0.6	9
168	A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation. <i>Blood</i> , 2019, 134, 4318-4318.	0.6	9
169	A Phase II Study of Dasatinib in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL/SLL).. <i>Blood</i> , 2007, 110, 3126-3126.	0.6	9
170	Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL. <i>Blood</i> , 2015, 126, 4158-4158.	0.6	9
171	Safety of idelalisib in B-cell malignancies: Integrated analysis of eight clinical trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18030-e18030.	0.8	9
172	Mcl-1 and Bcl-2 levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies. <i>Molecular Oncology</i> , 2022, 16, 1153-1170.	2.1	9
173	Phosphoinositide 3-Kinase Inhibition in Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 329-339.	0.9	8
174	Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities " is there an optimal dose?. <i>Expert Review of Hematology</i> , 2017, 10, 707-718.	1.0	8
175	Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL. <i>Blood</i> , 2019, 134, 1745-1745.	0.6	8
176	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. <i>Blood</i> , 2013, 122, 86-86.	0.6	8
177	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow " A proof of concept study. <i>PLoS ONE</i> , 2018, 13, e0193249.	1.1	8
178	Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study. <i>Blood</i> , 2021, 138, 391-391.	0.6	8
179	Physical Examination for the Academic Psychiatrist: Primer and Common Clinical Scenarios. <i>Academic Psychiatry</i> , 2016, 40, 321-327.	0.4	7
180	Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against <i>IGHV1-69</i> germline gene-based B-CLL. <i>MAbs</i> , 2016, 8, 787-798.	2.6	7

#	ARTICLE	IF	CITATIONS
181	Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL. <i>Blood</i> , 2019, 133, 990-992.	0.6	7
182	Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib. <i>Leukemia</i> , 2020, 34, 3404-3407.	3.3	7
183	The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 807-826.	0.9	7
184	LOXO-305: Targeting C481S Bruton Tyrosine Kinase in Patients with Ibrutinib-Resistant CLL. <i>Blood</i> , 2019, 134, 478-478.	0.6	7
185	Functional Somatic and Germline Variants in the NF- κ B Pathway in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 560-560.	0.6	7
186	Characterization of selective and potent PI3K δ inhibitor (PI3KD-IN-015) for B-Cell malignances. <i>Oncotarget</i> , 2016, 7, 32641-32651.	0.8	7
187	Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 32.e1-32.e10.	0.6	7
188	Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 197, 207-211.	1.2	7
189	Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?. <i>Leukemia and Lymphoma</i> , 2010, 51, 1382-1385.	0.6	6
190	Insulin Receptor Activation in Deletion 11q Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2011, 17, 2605-2607.	3.2	6
191	B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292. <i>ImmunoTargets and Therapy</i> , 2014, 3, 29.	2.7	6
192	Ibrutinib: searching for a partner drug. <i>Lancet Oncology</i> , The, 2019, 20, 3-5.	5.1	6
193	A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. <i>Blood</i> , 2019, 134, 1763-1763.	0.6	6
194	Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008, 112, 972-972.	0.6	6
195	Altered Expression of Functional Proteins in CD4 Regulatory T Cells during Therapy with Idelalisib. <i>Blood</i> , 2015, 126, 1735-1735.	0.6	6
196	A multicenter phase II study of venetoclax plus dose-adjusted R-EPOCH (VR-EPOCH) for Richter's syndrome.. <i>Journal of Clinical Oncology</i> , 2020, 38, 8004-8004.	0.8	6
197	Prospective Evaluation of FDG-PET Imaging of Treatment Response in Relapsed Follicular Lymphoma.. <i>Blood</i> , 2007, 110, 2331-2331.	0.6	6
198	A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2021, 39, 1099-1105.	1.2	5

#	ARTICLE	IF	CITATIONS
199	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018, 132, 145-145.	0.6	5
200	NF- κ B Pathway Mutations Modulate Cell Survival and Ibrutinib Response In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 670-670.	0.6	5
201	Phase 3 zanubrutinib (BGB-3111) vs bendamustine + rituximab (BR) in patients (pts) with treatment-naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS7581-TPS7581.	0.8	5
202	A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. <i>British Journal of Haematology</i> , 2017, 178, 820-823.	1.2	4
203	Opportunistic Infections (OIs) in Patients with Hematologic Malignancies (HM) Treated with Bruton's Tyrosine Kinase (BTK) and Phosphoinositide 3 Kinase (PI3K) Inhibitors: An 8-Year Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, S699-S699.	0.4	4
204	Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. <i>Leukemia and Lymphoma</i> , 2018, 59, 1986-1989.	0.6	4
205	ME-401-003 (TIDAL): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 Investigating Continuous and Intermittent Dosing Schedules in Patients with Relapsed/Refractory Follicular Lymphoma. <i>Blood</i> , 2019, 134, 5244-5244.	0.6	4
206	Increased Local Disorder of DNA Methylation Forms the Basis of High Intra-Leukemic Epigenetic Heterogeneity and Enhances CLL Evolution. <i>Blood</i> , 2013, 122, 596-596.	0.6	4
207	Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL. <i>Blood</i> , 2016, 128, 231-231.	0.6	4
208	Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2021, 138, 640-640.	0.6	4
209	Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 22-23.	0.6	4
210	Ibrutinib: coming of age?. <i>Blood</i> , 2018, 131, 1880-1882.	0.6	3
211	DUO delivers for duvelisib. <i>Blood</i> , 2018, 132, 2422-2424.	0.6	3
212	Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S283.	0.2	3
213	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	0.6	3
214	High-grade heart block associated with ibrutinib therapy. <i>HeartRhythm Case Reports</i> , 2021, 7, 391-394.	0.2	3
215	Obatoclox in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL. <i>Blood</i> , 2011, 118, 2865-2865.	0.6	3
216	Chronic Lymphocytic Leukemia Patients with IGHV Genes Carrying Only Silent Mutations Have A Longer Time From Diagnosis to Initial Therapy Than Patients Expressing B-Cell Receptors with No Somatic Mutations. <i>Blood</i> , 2011, 118, 288-288.	0.6	3

#	ARTICLE	IF	CITATIONS
217	Enhancer Landscapes Reveal Transcription Factor Network Dependencies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 436-436.	0.6	3
218	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 522-522.	0.6	3
219	Genetic Determinants and Evolutionary History of Richter's Syndrome. <i>Blood</i> , 2020, 136, 47-48.	0.6	3
220	Preface. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, xiii-xiv.	0.9	2
221	A new era of treatment for chronic lymphocytic leukaemia?. <i>Lancet Oncology</i> , The, 2014, 15, 3-5.	5.1	2
222	Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware. <i>Leukemia and Lymphoma</i> , 2018, 59, 2767-2768.	0.6	2
223	Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia " PassÃ© Yet?. <i>HemaSphere</i> , 2019, 3, e275.	1.2	2
224	Targeting MCL-1 and BCL-2: a 1-2 punch. <i>Blood</i> , 2021, 137, 2711-2712.	0.6	2
225	The future of antibody therapy in chronic lymphocytic leukemia. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 323-336.	1.0	2
226	Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study. <i>Blood</i> , 2018, 132, 1856-1856.	0.6	2
227	Mass Cytometry Identifies T Cell Populations Associated with Severe Hepatotoxicity in CLL Patients on Upfront Idelalisib. <i>Blood</i> , 2018, 132, 4413-4413.	0.6	2
228	A Phase 2 Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Lymphomas.. <i>Blood</i> , 2007, 110, 1358-1358.	0.6	2
229	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	0.6	2
230	SF3B1 Mutation Alters The Selection Of 3' RNA Splice Sites In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 117-117.	0.6	2
231	Effect Of MYD88 Mutation In CLL On IRAK4 and BTK Inhibition In Vitro. <i>Blood</i> , 2013, 122, 4132-4132.	0.6	2
232	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3156-3156.	0.6	2
233	Acalabrutinib Increases Mitochondrial Priming and Enhances Venetoclax Sensitivity in CLL Cells. <i>Blood</i> , 2016, 128, 4346-4346.	0.6	2
234	BH3 Profiling Demonstrates That Restoration of Apoptotic Priming Contributes to Increased Sensitivity to PI3K Inhibition in Stroma-Exposed Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 974-974.	0.6	2

#	ARTICLE	IF	CITATIONS
235	Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents. <i>Blood</i> , 2019, 134, 3321-3321.	0.6	2
236	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	0.6	2
237	The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. <i>Blood</i> , 2020, 136, 3-4.	0.6	2
238	Idelalisib activates AKT via increased recruitment of PI3K $\hat{1}$ /PI3K $\hat{2}$ to BCR signalosome while reducing PDK1 in post-therapy CLL cells. <i>Leukemia</i> , 2022, 36, 1806-1817.	3.3	2
239	Genomic Approaches to Chronic Lymphocytic Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 157-171.	0.9	1
240	Reply to S. Opat et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 4094-4095.	0.8	1
241	For CLL cells, thereâ€™s no place like home. <i>Leukemia and Lymphoma</i> , 2019, 60, 3347-3349.	0.6	1
242	Inverting the BTK-BCL2 order. <i>Blood</i> , 2020, 135, 2205-2207.	0.6	1
243	AKT: a key to RT?. <i>Blood</i> , 2021, 137, 582-584.	0.6	1
244	Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 648925.	1.8	1
245	Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial. <i>Blood</i> , 2019, 134, 4312-4312.	0.6	1
246	High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). <i>Blood</i> , 2019, 134, 4291-4291.	0.6	1
247	Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies. <i>Blood</i> , 2019, 134, 1756-1756.	0.6	1
248	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. <i>Blood</i> , 2019, 134, 3039-3039.	0.6	1
249	A Phase I Study of Escalated Dose Subcutaneous Alemtuzumab Given Weekly with Rituximab In Relapsed CLL/SLL. <i>Blood</i> , 2010, 116, 1381-1381.	0.6	1
250	Phenotypic Changes Associated with Acute Reductions In Leukemia Cell Counts In Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Lenalidomide as Initial Therapy. <i>Blood</i> , 2010, 116, 59-59.	0.6	1
251	Shifts in Intra-Clonal Dynamics Rather Than Novel Mutations Are the Main Engine Driving Tumor Evolution in Relapsed CLL. <i>Blood</i> , 2011, 118, 284-284.	0.6	1
252	Sensitivity to Wnt Pathway Inhibition in CLL Is Associated with Specific Gene Expression Signatures. <i>Blood</i> , 2011, 118, 801-801.	0.6	1

#	ARTICLE	IF	CITATIONS
253	Risk Alleles Identified in Genome-Wide Association Studies Are Associated with Expression Quantitative Trait Loci in Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2875-2875.	0.6	1
254	The Clonal Architecture of CXCR4 mutations in Waldenstrom's Macroglobulinemia Shows Highly Variable Subclonal Distribution, and Multiple Mutations within Individual Patients Indicative of Targeted Genomic Instability. Blood, 2015, 126, 1486-1486.	0.6	1
255	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. Blood, 2015, 126, 1713-1713.	0.6	1
256	A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL. Blood, 2015, 126, 4159-4159.	0.6	1
257	Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphocytic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen.. Blood, 2005, 106, 2125-2125.	0.6	1
258	The Molecular Basis for BCL-2 Oncogene Addiction in CLL.. Blood, 2005, 106, 5008-5008.	0.6	1
259	High Resolution Genomic Analysis In CLL Demonstrates Genomic Stability In Untreated Patients and Novel Markers of Progression In Treated Patients. Blood, 2010, 116, 2426-2426.	0.6	1
260	The Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia. Blood, 2012, 120, 5-5.	0.6	1
261	Interim Positron Emission Tomography (iPET) Assessed Using Deauville Score for Patients with Follicular Lymphoma Receiving First-Line Chemoimmunotherapy. Blood, 2020, 136, 37-38.	0.6	1
262	Reply to J. Mehta. Journal of Clinical Oncology, 2009, 27, e139-e140.	0.8	0
263	Gastric mucosa-associated lymphoid tissue lymphoma resistant to <i>Helicobacter pylori</i> eradication: what's the best option?. Leukemia and Lymphoma, 2013, 54, 899-900.	0.6	0
264	Obinutuzumab: its use in the management of chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs, 2015, 3, 843-853.	0.5	0
265	The rosy future of BCL-2 inhibition in chronic lymphocytic leukemia: pursuit of a worthy target. Leukemia and Lymphoma, 2015, 56, 2755-2756.	0.6	0
266	Advances in drug-based therapies in chronic lymphocytic leukemia and future prospects. Advances in Cell and Gene Therapy, 2019, 2, e51.	0.6	0
267	4321 Personalization of T cell production for cellular immunotherapy. Journal of Clinical and Translational Science, 2020, 4, 15-15.	0.3	0
268	A prospective study of minimal residual disease in patients with diffuse large B-cell lymphoma using an Ig-NGS assay. Leukemia and Lymphoma, 2021, 62, 478-481.	0.6	0
269	Abstract 1097: Mechanisms of primary and acquired resistance to venetoclax in chronic lymphocytic leukemia (CLL). , 2021, , .		0
270	Chronic Lymphocytic Leukemia: So Much Progress, Still Challenges Ahead. Hematology/Oncology Clinics of North America, 2021, 35, xiii-xiv.	0.9	0

#	ARTICLE	IF	CITATIONS
271	Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study.. Blood, 2006, 108, 4989-4989.	0.6	0
272	Long-Term Follow-Up of Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission: Bone Marrow Involvement at Harvest and PCR Detectable Disease after Ex Vivo Purging Predict Relapse.. Blood, 2006, 108, 3041-3041.	0.6	0
273	Non-Myeloablative Allogeneic Transplantation for Hodgkinâ€™s and Non-Hodgkinâ€™s Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. Blood, 2007, 110, 3041-3041.	0.6	0
274	BH3 Profiling Demonstrates Decreased Mitochondrial Priming for Apoptosis In Primary CLL Cells Exposed to Stroma. Blood, 2010, 116, 692-692.	0.6	0
275	Response to Dasatinib In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Correlates with p-Lyn and p-Syk. Blood, 2010, 116, 2457-2457.	0.6	0
276	Amplification of 6p Associated with Familial CLL. Blood, 2010, 116, 2432-2432.	0.6	0
277	Improved Outcome of CLL Patients with Leukemic Clones Expressing Mutated IGHV May Not Be Due to An Inability to Bind (auto)Antigen In Vivo. Blood, 2010, 116, 2441-2441.	0.6	0
278	Novel Germline Genetic Variants Associated with Familial Chronic Lymphocytic Leukemia (CLL). Blood, 2011, 118, 465-465.	0.6	0
279	Large-Scale CLL Genome Analysis Reveals Novel Cancer Genes, Including SF3B1. Blood, 2011, 118, 463-463.	0.6	0
280	Increased Dose Rituximab Followed by Maintenance Rituximab As Initial Therapy for Indolent B Cell Lymphomas: A Phase II Trial,. Blood, 2011, 118, 3716-3716.	0.6	0
281	Rearrangement of 14q32 in the Absence of t(14;18) Is Associated with Short Time to First Treatment in Chronic Lymphocytic Leukemia. Blood, 2011, 118, 1438-1438.	0.6	0
282	MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,. Blood, 2011, 118, 3669-3669.	0.6	0
283	LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2728-2728.	0.6	0
284	Somatic Mutation As a Mechanism of Wnt/ β 2-Catenin Pathway Activation in CLL. Blood, 2012, 120, 559-559.	0.6	0
285	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 2012, 120, 1892-1892.	0.6	0
286	The Relative Significance of ZAP-70 Promoter Methylation As a Prognostic Factor in Previously Untreated Chronic Lymphocytic Leukemia: Validation of Results Using a Second Large CLL Research Consortium (CRC) Patient Data Set. Blood, 2012, 120, 3865-3865.	0.6	0
287	Prior Treatment with Chemotherapy Is Associated with Poor Outcomes of High Risk Skin Cancers in Patients with Chronic Lymphocytic Leukemia. Blood, 2012, 120, 3920-3920.	0.6	0
288	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. Blood, 2012, 120, 1980-1980.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Somatic and Germline Copy Neutral Loss of Heterozygosity Are Common in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012, 120, 4567-4567.	0.6	0
290	Inhibition Of Lyn and Syk By Treatment With Dasatinib, Fludarabine, and Rituximab Correlates With Apoptosis and Clinical Response In Patients With Relapsed CLL. <i>Blood</i> , 2013, 122, 5300-5300.	0.6	0
291	The Bruton Tyrosine Kinase (Btk) Inhibitor ACP-196: Marked Activity in Relapsed/Refractory CLL with a Favorable Safety Profile. <i>Blood</i> , 2015, 126, 831-831.	0.6	0
292	Molecular Remission One Year Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia Predicts Relapse-Free and Overall Survival: A Multi-Institutional Landmark Analysis. <i>Blood</i> , 2015, 126, 4340-4340.	0.6	0
293	Microenvironmental Interactions up-Regulate CD20 Expression in CLL B Cells through the CXCR4/SDF-1 Axis: Implications for CD20-Targeting Antibodies and the Use of BCR-Inhibitors in Combination. <i>Blood</i> , 2015, 126, 4124-4124.	0.6	0
294	Dynamic BH3 Profiling Predicts Patient Response and MRD Status in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Frontline Treatment with Kinase Inhibitor Plus FCR (KI+FCR). <i>Blood</i> , 2018, 132, 4395-4395.	0.6	0
295	Clonal and Single Cell Dynamics of Resistance to Graft-Versus-Leukemia (GvL) in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2018, 132, 820-820.	0.6	0
296	Idelalisib Plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL. <i>Blood</i> , 2018, 132, 5564-5564.	0.6	0
297	High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 2571-2571.	0.6	0
298	Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL). <i>Blood</i> , 2019, 134, 516-516.	0.6	0
299	Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study. <i>Blood</i> , 2019, 134, 3048-3048.	0.6	0
300	Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20004-e20004.	0.8	0
301	Novel Mechanisms of Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia By Whole Genome Methylome Sequencing. <i>Blood</i> , 2021, 138, 4361-4361.	0.6	0
302	Characterizing Specificities of Chronic Lymphoid Leukemia Harboring a BCL2 rearrangement. <i>Blood</i> , 2020, 136, 29-30.	0.6	0
303	Evolving Treatment Patterns in Chronic Lymphocytic Leukemia Among Experts and Community Practitioners: Analysis of an Online Decision Support Tool. <i>Blood</i> , 2020, 136, 41-42.	0.6	0